Author pages are created from data sourced from our academic publisher partnerships and public sources.
- Publications
- Influence
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer.
- I. Tannock, R. de Wit, +9 authors M. Eisenberger
- Medicine
- The New England journal of medicine
- 7 October 2004
BACKGROUND
Mitoxantrone plus prednisone reduces pain and improves the quality of life in men with advanced, hormone-refractory prostate cancer, but it does not improve survival. We compared such… Expand
Design and end points of clinical trials for patients with progressive prostate cancer and castrate levels of testosterone: recommendations of the Prostate Cancer Clinical Trials Working Group.
- H. Scher, S. Halabi, +17 authors M. Hussain
- Medicine
- Journal of clinical oncology : official journal…
- 1 March 2008
PURPOSE
To update eligibility and outcome measures in trials that evaluate systemic treatment for patients with progressive prostate cancer and castrate levels of testosterone.
METHODS
A committee… Expand
Measuring health-related quality of life.
- D. Osoba, I. Tannock
- Medicine
- Journal of clinical oncology : official journal…
- 1 July 1999
Prognostic role of neutrophil-to-lymphocyte ratio in solid tumors: a systematic review and meta-analysis.
- A. Templeton, M. McNamara, +9 authors E. Amir
- Medicine
- Journal of the National Cancer Institute
- 1 June 2014
BACKGROUND
Inflammation may play an important role in cancer progression, and a high neutrophil-to-lymphocyte ratio (NLR) has been reported to be a poor prognostic indicator in several malignancies.… Expand
Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer: a Canadian randomized trial with palliative end points.
- I. Tannock, D. Osoba, +8 authors K. Murphy
- Medicine
- Journal of clinical oncology : official journal…
- 1 June 1996
PURPOSE
To investigate the benefit of chemotherapy in patients with symptomatic hormone-resistant prostate cancer using relevant end points of palliation in a randomized controlled trial.
PATIENTS… Expand
Drug penetration in solid tumours
- A. Minchinton, I. Tannock
- Biology, Medicine
- Nature Reviews Cancer
- 1 August 2006
To be most effective anticancer drugs must penetrate tissue efficiently, reaching all the cancer cells that comprise the target population in a concentration sufficient to exert a therapeutic effect.… Expand
Drug resistance and the solid tumor microenvironment.
- O. Trédan, C. Galmarini, K. Patel, I. Tannock
- Medicine, Biology
- Journal of the National Cancer Institute
- 3 October 2007
Resistance of human tumors to anticancer drugs is most often ascribed to gene mutations, gene amplification, or epigenetic changes that influence the uptake, metabolism, or export of drugs from… Expand
Docetaxel plus prednisone or mitoxantrone plus prednisone for advanced prostate cancer: updated survival in the TAX 327 study.
- D. Berthold, G. Pond, F. Soban, R. de Wit, M. Eisenberger, I. Tannock
- Medicine
- Journal of clinical oncology : official journal…
- 10 January 2008
PURPOSE
The TAX 327 study compared docetaxel administered every 3 weeks (D3), weekly docetaxel (D1), and mitoxantrone (M), each with prednisone (P), in 1,006 men with metastatic hormone-resistant… Expand
Acid pH in tumors and its potential for therapeutic exploitation.
- I. Tannock, D. Rotin
- Chemistry, Medicine
- Cancer research
- 15 August 1989
Measurement of pH in tissue has shown that the microenvironment in tumors is generally more acidic than in normal tissues. Major mechanisms which lead to tumor acidity probably include the production… Expand
Fatigue, menopausal symptoms, and cognitive function in women after adjuvant chemotherapy for breast cancer: 1- and 2-year follow-up of a prospective controlled study.
- H. M. Fan, N. Houédé-Tchen, +4 authors I. Tannock
- Medicine
- Journal of clinical oncology : official journal…
- 1 November 2005
PURPOSE
We previously evaluated fatigue, menopausal symptoms, and cognitive dysfunction in patients receiving adjuvant therapy for breast cancer and matched healthy women. Here we report assessment… Expand